Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Carlsmed (CARL) EPS (Weighted Average and Diluted) (2024 - 2026)

Carlsmed filings provide 2 years of EPS (Weighted Average and Diluted) readings, the most recent being $0.03 for Q4 2025.

  • On a quarterly basis, EPS (Weighted Average and Diluted) rose 102.63% to $0.03 in Q4 2025 year-over-year; TTM through Dec 2025 was -$2.98, a N/A change, with the full-year FY2025 number at -$2.12, up 65.3% from a year prior.
  • EPS (Weighted Average and Diluted) hit $0.03 in Q4 2025 for Carlsmed, up from -$0.4 in the prior quarter.
  • In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $0.03 in Q4 2025 to a low of -$2.06 in Q3 2024.